Castle Biosciences (NASDAQ:CSTL – Get Free Report) is one of 233 public companies in the “Healthcare Providers & Services” industry, but how does it weigh in compared to its peers? We will compare Castle Biosciences to similar businesses based on the strength of its risk, analyst recommendations, valuation, dividends, institutional ownership, earnings and profitability.
Volatility & Risk
Castle Biosciences has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.Comparatively, Castle Biosciences’ peers have a beta of 0.98, meaning that their average stock price is 2% less volatile than the S&P 500.
Institutional & Insider Ownership
92.6% of Castle Biosciences shares are owned by institutional investors. Comparatively, 56.7% of shares of all “Healthcare Providers & Services” companies are owned by institutional investors. 6.1% of Castle Biosciences shares are owned by company insiders. Comparatively, 15.0% of shares of all “Healthcare Providers & Services” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Castle Biosciences and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Castle Biosciences | 1 | 1 | 8 | 1 | 2.82 |
| Castle Biosciences Competitors | 1877 | 7751 | 13384 | 833 | 2.55 |
Castle Biosciences currently has a consensus price target of $46.50, indicating a potential upside of 37.61%. As a group, “Healthcare Providers & Services” companies have a potential upside of 13.38%. Given Castle Biosciences’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Castle Biosciences is more favorable than its peers.
Profitability
This table compares Castle Biosciences and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Castle Biosciences | -6.10% | -4.89% | -4.06% |
| Castle Biosciences Competitors | -7.86% | -135.41% | -1.59% |
Valuation & Earnings
This table compares Castle Biosciences and its peers revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Castle Biosciences | $344.23 million | -$24.16 million | -43.88 |
| Castle Biosciences Competitors | $21.44 billion | $301.67 million | -1.73 |
Castle Biosciences’ peers have higher revenue and earnings than Castle Biosciences. Castle Biosciences is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Summary
Castle Biosciences beats its peers on 8 of the 13 factors compared.
About Castle Biosciences
Castle Biosciences, Inc. is a molecular diagnostics company that develops and commercializes tests intended to help physicians make personalized treatment and care decisions. Its tests analyze biological features of tissue to provide information about disease behavior and patient risk. The company’s portfolio includes DecisionDx tests for conditions such as cutaneous melanoma, cutaneous squamous cell carcinoma and uveal melanoma. It also offers TissueCypher, a test designed to assess progression risk in patients with Barrett’s esophagus.
Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
